Page last updated: 2024-09-02

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and HIV Coinfection

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with HIV Coinfection in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Angerer, A; Antke, C; Arendt, G; Carey, P; Husstedt, IW; Koutsilieri, E; Maschke, M; Meisner, F; Müller, HW; Neuen-Jacob, E; Nolting, T; Obermann, M; Riederer, P; Scheller, C; Sopper, S; Ter Meulen, V1

Other Studies

1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and HIV Coinfection

ArticleYear
Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses.
    Journal of neural transmission (Vienna, Austria : 1996), 2010, Volume: 117, Issue:6

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Benzamides; Case-Control Studies; CD4 Antigens; Chemokine CCL2; Dopamine; Galactosephosphates; HIV; HIV Infections; Homovanillic Acid; Humans; Male; Middle Aged; Pyrrolidines; Synaptic Transmission; Tomography, Emission-Computed, Single-Photon; Tropanes; Viral Load

2010